Acumen Pharmaceuticals, Inc. — Director's Dealing 2021

Jul 1, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Acumen Pharmaceuticals, Inc. (ABOS)
CIK: 0001576885
Period of Report: 2021-06-30

Reporting Person: Zuga Matt (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-1 Preferred Stock	$		Common Stock (15659)		Direct
Series B Preferred Stock	$		Common Stock (10528)		Direct
Stock Option (Right to Buy)	$0.75	2029-07-29	Common Stock (46420)		Direct
Stock Option (Right to Buy)	$1.19	2031-01-03	Common Stock (451369)		Direct

Footnotes

F1: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock will automatically convert into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. The Series A-1 Preferred and the Series B Preferred Stock have no expiration date.

F2: The shares underlying the option vest and become exercisable in 36 equal monthly installments beginning on July 29, 2019, such that the option shall be fully vested on July 29, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such date.

F3: 25% of the shares underlying the option shall vest and become exercisable on January 1, 2022; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.